BREAKING NEWS: President Trump Reschedules Cannabis to Schedule III

Washington, D.C. — Today marks one of the most consequential moments in modern American drug policy.

In a decision that immediately reshapes the legal, economic, and political future of cannabis, President Donald Trump has signed an executive order directing federal agencies to finalize the reclassification of cannabis from Schedule I to Schedule III under the Controlled Substances Act, stating,

“Today I am pleased to announce I will be signing an executive order to move marijuana from a schedule one to a schedule 3 controlled substance with legitimate medical uses. We have people begging for me to do this. People that are in great pain. For decades this action has been requested by American patients, ” during his speech on December 18^th, 2025. 

For more than five decades, cannabis occupied the most restrictive category of controlled substances, defined as having no accepted medical use and a high potential for abuse. That classification placed it alongside heroin, despite widespread medical programs, state-level legalization, and a growing body of scientific evidence supporting therapeutic use.

Today, that contradiction officially ended.

While this action stops short of full federal legalization, it represents the single most impactful federal cannabis reform ever enacted. For patients, operators, investors, and advocates, the implications are immediate and profound.

President Trump also asked Congress, “to reconsider its classification of hemp derived CBD to ensure seniors can access CBD products they have found beneficial for pain and other reasons.” Noting, “Some people are literally dying with tremendous pain and in many cases, this can stop it.”

Let’s dive into what this means for the cannabis industry.

Cannabis Rescheduled to Schedule III: What Changed Today

The rescheduling decision follows a formal, multi-agency review process involving the Department of Health and Human Services and the Drug Enforcement Administration. After evaluating medical utility, abuse potential, and scientific data, regulators concluded that cannabis no longer meets the criteria for Schedule I classification.

Cannabis is now listed as a Schedule III substance, placing it in the same category as ketamine, testosterone, and certain pain medications, all drugs recognized for medical use but subject to regulatory oversight.

This change represents a fundamental acknowledgment by the federal government: cannabis does have accepted medical use.

That admission alone dismantles decades of policy built on denial rather than evidence.

Why Schedule III Is a Big Deal: The Legal Mechanics Explained

To understand the magnitude of today’s decision, it’s important to understand what scheduling actually does.

Schedule I status did more than criminalize cannabis. It isolated it from research, banking, tax fairness, and regulatory consistency. It created a system where cannabis could be legal in 42 states for medical use yet considered federally worthless as medicine.

Schedule III changes that reality.

Under this classification, cannabis is no longer subject to IRS Code 280E, a tax provision originally designed to punish illicit drug traffickers. For years, 280E prevented cannabis businesses from deducting ordinary operating expenses such as rent, payroll, insurance, marketing, and utilities.

The result was devastating. Effective tax rates routinely exceeded 60 to 80 percent, pushing otherwise successful companies into insolvency. With today’s rescheduling, that tax burden is lifted.

Additionally, it will open more avenues for cannabis research, leading the way for more physician support, cannabinoid therapies, and guidance for medical patients.

The Economic Impact: How Rescheduling Transforms the Cannabis Business Model

For the legal cannabis industry, Schedule III changes the underlying economics almost overnight.

Companies that were generating strong revenue but struggling to survive now have a realistic path to profitability. Cash flow improves instantly, debt becomes more manageable, and expansion plans once shelved can be revisited.

The industry moves from a punishment-based framework to a regulatory one.

This shift is expected to:

• Increase reinvestment in employees and benefits
• Improve compliance and product safety
• Accelerate innovation and research
• Encourage long-term business planning

For the first time, cannabis operators are being treated like regulated businesses instead of tolerated criminals.

Who Is Most Affected by Cannabis Rescheduling?

Today’s monumental executive order by President Donald Trump has significant effects on numerous sectors of the industry.

Patients and Healthcare Providers

Patients stand to benefit significantly from expanded research opportunities. Schedule I status made cannabis one of the hardest substances in the world to study. Researchers faced extraordinary hurdles just to access plant material. Schedule III removes many of those barriers.

This means more clinical trials, better understanding of cannabinoid therapies, improved dosing guidelines, and greater physician confidence. Over time, this could lead to more standardized medical cannabis programs and broader integration into healthcare systems.

Cannabis Operators and Entrepreneurs

Licensed cannabis businesses are among the most immediately impacted. For years, operators have been forced to choose between growth and survival. Today, that equation changes. Companies can now operate with tax structures similar to other industries, improving margins and stabilizing operations. This creates space for responsible growth rather than reckless and hopeful expansion.

Employees and Local Economies

Healthier businesses mean more stable jobs, improved working conditions, and increased economic contributions to local communities. Cannabis already generates billions in tax revenue at the state level and rescheduling strengthens that impact rather than undermining it.

Wall Street Reacts: Cannabis Stocks Surge on Federal Reform News

Financial markets responded immediately after the announcement.

Cannabis stocks across U.S. and Canadian exchanges saw increased trading volume as investors recalibrated risk and long-term valuation models. For years, federal prohibition created uncertainty that kept institutional capital on the sidelines.

Schedule III removes one of the largest systemic risks facing the sector. Analysts quickly revised earnings forecasts, noting that eliminating 280E alone could dramatically improve profitability across the board.

This is not a speculative rally; it is a structural repricing of the industry.

Cannabis Stock Winners: Companies Positioned for Immediate Upside

Several companies emerged as early beneficiaries of the announcement, particularly U.S.-based multi-state operators with strong retail footprints and disciplined operations.

Green Thumb Industries

Widely regarded as one of the most operationally efficient cannabis companies in the U.S., Green Thumb is now positioned to translate revenue growth into sustained profitability. Analysts point to strong brand performance and conservative expansion as key strengths in a post 280E environment.

Curaleaf

As one of the largest cannabis operators globally, Curaleaf’s scale becomes significantly more powerful under Schedule III. Improved cash flow allows for reinvestment in research, retail, and international opportunities.

Trulieve

Known for operational discipline and market dominance in key states, Trulieve is expected to see immediate margin expansion following rescheduling. Investors view the company as well-positioned for long-term stability.

Cresco Labs

With a strong wholesale strategy and branded product portfolio, Cresco stands to benefit from improved liquidity and expansion flexibility as tax burdens ease.

Canadian companies with U.S. exposure, including Tilray Brands (TLRY ) and Canopy Growth (CGC ), also saw renewed interest as investors speculated on improved access to U.S. markets and future federal reforms.

Cannabis Industry Turning Point After Schedule III Rescheduling

For more than a decade, the cannabis industry has been defined by contradiction. Legal but illegal, popular but punished, and regulated yet excluded.

Rescheduling does not eliminate every challenge, but it removes the most suffocating one.

Operators can now focus on building resilient companies instead of navigating constant existential threats. Expect to see increased investment in employee training, consumer education, product safety, and sustainable practices.

This shift marks the industry’s transition from survival mode to strategy mode.

Can President Trump’s Executive Order Be Reversed or Overturned?

While no federal policy is entirely immune from political change, reversing this decision would be difficult.

The rescheduling followed established administrative procedures and scientific review. Any attempt to undo it would require comparable evidence and justification; not merely ideological opposition that has driven the restriction for decades.

Congress retains authority over drug scheduling, but legislative reversal is unlikely. Courts also tend to defer to agency expertise when decisions are grounded in formal review processes.

This change is not only symbolic, but durable.

Advocacy Perspective: A Victory But Not the Finish Line

Advocates are celebrating today’s announcement, but with measured expectations.

Schedule III does not equal legalization. It does not automatically expunge records, nor does not establish interstate commerce or guarantee banking access.

However, it does something equally important: it dismantles the federal government’s most damaging cannabis lie. By acknowledging medical value, the foundation is laid for future reforms, including descheduling, criminal justice measures, and comprehensive regulatory frameworks.

This moment validates decades of advocacy, patient testimony, and scientific persistence.

What This Means for U.S. Cannabis Policy Going Forward

Today’s decision changes the trajectory of cannabis reform in America.

Federal agencies now operate from a place of recognition rather than denial. Lawmakers debating future reforms do so with science on the record. And investors assess cannabis as an emerging regulated industry, not a legal gray market.

This shift makes additional reform more achievable, more defensible, and more likely.

The Global Signal: America Begins to Catch Up

Internationally, today’s rescheduling sends a powerful message.

The United States, long criticized for outdated cannabis policy, is beginning to align with global trends that treat cannabis as a public health and regulatory issue rather than a criminal one.

This move strengthens U.S. credibility in international drug policy discussions and signals openness to continued modernization.

Cannabis Rescheduling to Schedule III: Final Takeaway

This is not the end of prohibition. But it may be remembered as the moment federal denial finally collapsed.

For patients, it means validation.

For businesses, it means sustainability.

For advocates, it means momentum.

After decades of operating in contradiction, the cannabis industry has finally crossed a federal threshold that many believed would never come.

Today was not just a policy change, it was history, and the beginning of a new chapter for cannabis in America.